Related Experiment Video
Updated: Aug 13, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Parvalbumin interneurons in Alzheimer's disease: Physiological insights and pathophysiological mechanisms
Mengyan Wu1,2, Xingdong Zeng1,2, Yongle Cai1
1Institute for Fetology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China.
Abstract:
Fast-spiking parvalbumin-positive (PV+) interneurons, a specialized class of inhibitory neurons, possess unique morphological and functional properties that govern spatiotemporal precision in local microcircuits, large-scale network synchronization, and memory-related computations. Since their initial identification in the late 19th century, technological innovations in cellular neuroscience have progressively elucidated the multifaceted roles of these neurons. In this review, we first delineate the embryonic origins and developmental trajectory of PV+ interneurons, emphasizing their unique properties for high-frequency firing with remarkable temporal precision. These specialized features enable PV+ interneurons to orchestrate network oscillations and critically modulate memory encoding, consolidation, and retrieval, despite their substantial metabolic demands. We subsequently integrate multiple lines of evidence implicating region- and subtype-specific PV+ interneuron impairment as a pivotal pathological hallmark in Alzheimer's disease (AD). Furthermore, we dissect molecular and cellular mechanisms driving PV+ interneuron dysfunction in AD, including numerical alterations, morphological remodeling, and electrophysiological disruptions. Critically, we propose that the pathological transformation of PV+ interneuron physiology emerges as a key driver in AD progression, bridging cellular dysfunction to system-level cognitive failure.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Neural Regulation
Parkinson Disease ll: Pathophysiology

